



PTO/SB/08A (10-07)
Approved for use through 10/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

USPTO Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 12

Complete if Known

Application Number	10/518,003
Filing Date	March 14, 2005
First Named Inventor	Daniel S. MARTIN
Art Unit	1623
Examiner Name	Lawrence E. Crane
Attorney Docket Number	636-C-PCT-US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	1	US 5,641,670	6-24-1997	TRECO et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	2	WO 02/45720 A1	06-13-2002	SLOAN KETTERING INST.	
				FOR CANCER RES.	

Examiner Signature	/Lawrence Crane/ (Date 3/1/2008) Considered
--------------------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/518,003
Filing Date	March 14, 2005
First Named Inventor	Daniel S. MARTIN
Art Unit	1623
Examiner Name	Lawrence E. Crane
Attorney Docket Number	636-C-PT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	3	PCT International Preliminary Examination Report for SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, PCT/US01/46886 (Atty. Dkt. #636-A-PCT), "Treatment of cancer by reduction of intracellular energy and pyrimidines," Filed December 4, 2001, Dated July 25, 2003.	
/L.C./	4	Amarante-Mendes, G.P., Finucane, D.M., Martin, S.J., Cotter, T.G., Salvesen, G.S. and Green, D.R., 1996, "Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death," Cell Death Differ., 5:298-306.	
/L.C./	5	Batova, A., Diccianni, M.B., Omura, Minamisawa, M., Yu, J., Carrera, C.J., Bridgeman, L.J., Kung, F.H., Pullen, J., Arnylung, M.D. and Yu, A.L., 1999, Use of alanosine as a methyladenosine phosphorylase - selective therapy for T-cell acute lymphoblastic leukemia in vitro," Cancer Res., 59:1492-1497.	
/L.C./	6	Berger, N.A., and Berger, S.J., 1986, "Metabolic consequences of DNA damage: The role of poly (ADP-ribose) polymerase as mediator of the suicide response," In: L. Grossman, A.C. Upton, (eds.) Mechanisms of DNA Damage and Repair, pp. 357-363. New York: Plenum Publishing Corporation.	
/L.C./	7	Berns, A., May 2002, "Senescence: A companion in chemotherapy?" Cancer Cell, 309-311.	
/L.C./	8	Bertino, J.R., 1990, "Leucovorin rescue revisited: Editorial," J. Clin. Oncol., 8 (2):193-195.	
/L.C./	9	Bissett, D., Mcleod, H.L., Sheedy, B., Collier, M., Pithavala, Y., Paradiso, L., Pitsiladis, M. and Cassidy, J., 2001, "Phase 1 dose-escalation and pharmacokinetic study of a novel folate analogue A G 2034," Br. J. Cancer, 84:308-312.	
/L.C./	10	Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P. and Lipton, S.A., 1995, "Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or metric oxide/superoxide in cortical cell cultures," Proc. Natl. Acad. Sci. USA, 92:7162-7166.	
/L.C./	11	Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Kucks, Z. and Kolesnick, R., 1995, "Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals," Cell, 82:405-411.	
/L.C./	12	Boulares, A.H., Yokovlev, A.G., Ivanova, V., Stoica, B.A., Wang, G., Iyer, S. and Smulson, M., 1999, "Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase-3 resistant PARP mutant increases rates of apoptosis in transfected cells," J. Biol. Chem., 274:22932-22940.	

Examiner Signature	/Lawrence Crane/ (636-317/2008)	Considered
--------------------	---------------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
Sheet	3	of	12
		Attorney Docket Number	636-C-PT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	13	Britten, C.D., Rowinsky, E.K., Baker, S.D., Weiss, G.R., Smith, L., Stephenson, J., Rothenberg, M., Smetzer, L., Cramer, J., Collins, W., Von Hoff, D.D., and Eckhardt, S.G., 2000, "A Phase 1 and pharmacokinetic study of the mitochondrial-specific chondracynine dye analog MKT 011," Clin. Cancer Res., 6:42-49.	
/L.C./	14	Bronder, J.L. and Moran, R.G., 2002, "Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function," Cancer Res., 62:5236-5241.	
/L.C./	15	Budiardjo, H., Walker, D.L., Svingen, P.A., Buckwalter, C.A., Desnoyers, S., Eckdahl, S., Shah, G.M., Poirier, G.G., Reid, J.M., Ames, M.M., and Kaufmann, S.H., 1998, "6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin," Clinical Cancer Research, 4:117-30.	
/L.C./	16	Cahill, D.P., Kinzler, K.W., Vogelstein, B. and Lengauer, C., 1999, "Genetic instability and Darwinian selection tumors," Trends in Cell Biology, 57-60.	
/L.C./	17	Carson, D.A., Seto, S., Wasson, B., and Carrera, C., 1986, "DNA strand breaks, NAD metabolism, programmed cell death," Exp. Cell. Res., 164:273-281.	
/L.C./	18	Chatterjee, S., Hirota, H., Belli, C.A., Berger, S.J. and Berger, N.A., 1997, "Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP 78," Cancer Res., 57:5112-5116.	
/L.C./	19	Chen, Z.H., Zhang, H. and Savarese, T.M., 1996, "Gene deletion chemoselectivity: codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, and the - and -interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy," Cancer Res., 56:1083-1090.	
/L.C./	20	Constantini, P., Chemyak, B.V., Petronilli, V. and Bernardi, P., 1996, "Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites," J. Biol. Chem., 271:6746-6751.	
/L.C./	21	Cory, A.H., and Cory, J.G., 1994, "Use of nucleoside Kinase deficient mouse leukemia L1210 cell lines to determine metabolic routes of activation of antitumor nucleoside analogs," Adv. Enzyme Regul., 34:1-12.	
/L.C./	22	Cotter, T.G., Lenon, S.V., Glynn, J.G. and Martin, S.J., 1990, "Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells," Anticancer Res., 10:1153-1160.	

Examiner Signature	/Lawrence Crane/ Date 3/7/2008
	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/518,003
Filing Date	March 14, 2005
First Named Inventor	Daniel S. MARTIN
Art Unit	1623
Examiner Name	Lawrence E. Crane
Attorney Docket Number	636-C-PCT-US

Sheet 4 of 12

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	23	Dang, C.V. and Semenza, G.L., 1999, "Oncogenic alterations metabolism," Trends Biochem. Sci., 24:68-92.	
/L.C./	24	Dietrich, L.S., Kaplan, L., and Friedland, I.M., 1958, "Pyridine nucleotide metabolism: mechanism of action of the niacin antagonist, 6-aminonicotinamide," J. Biol. Chem. 233:964-968.	
/L.C./	25	Droin, N., Beauchemin, M., Solary, E. and Bertrand, R., 2000, "Identification of a caspase-2 isoform that behaves as endogenous inhibitor of the caspase cascade," Cancer Res., 60:7039-7047.	
/L.C./	26	Eguchi, Y., Shimizu, S., and Tsujimoto, Y., 1997, "Intracellular ATP levels determine cell fate by apoptosis or necrosis," Cancer Res., 57:1835-1840.	
/L.C./	27	Evtdienko, Y.V., Teplova, V.V., Sidosh, S.S., Ichas, F. and Mazal, J.P., 1996, "Microtubule-active drugs suppress the closure of the permeability transition pore in tumor mitochondria," FEBS Lett., 393:86-88.	
/L.C./	28	Fitch, J.H., Riscoe, M.K., Dana, B.W., Lawrence, H.J. and Ferro, A.J., 1986, "Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors," Cancer Res., 46:5409-5412.	
/L.C./	29	Formigli, L., Papucci, L., Tani, A., Schivone, N., Tempestine, A., Orlandini, G.E., Capaccioli, S. and Orlandini, S.Z., 2000, "Aponecrosis: Morphological and biochemical exploration of a synthetic process of cell death sharing apoptosis and necrosis," J. Cell Physiol. 182:41-49.	
/L.C./	30	Forrester, H.B., Albright, N., Ling, C.C. and Dewey, W.C., 2000, "Computerized video time-lapse analysis of apoptosis of REC: Myc cells X-radiated in different phases of the cell cycle," Radiat. Res., 154:625-639.	
/L.C./	31	Gaal, J.C., Smith, K.R., and Pearson, C.K., 1987, "Cellular euthanasia mediated by a nuclear enzyme: A central role for nuclear ADP-ribosylation in cellular metabolism," Trends Biochem. Sci., 12:129-130.	
/L.C./	32	Gewirtz, D.A., 1999, "A critical evaluation of mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin," Biochem. Pharm., 57:727-741.	

Examiner Signature

/Lawrence Crane (10/31/2006)

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
		Attorney Docket Number	636-C-PCT-US
Sheet	5	of	12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	33	Goldin, A., Kendetti, J.M., MacDonald, J.S., Muggia, F., Henney, J. and DeVita, V.T., 1981, "Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute," Eur. J. Cancer, 17:129.	
/L.C./	34	Green, D.R., 1998, "Apoptotic pathways: The roads to ruin," Cell, 94:695-698.	
/L.C./	35	Grindey, G.B., Lowe, J.K., Divekey, A.Y., and Hatake, M.T., 1976, "Potentiation by guanine nucleosides of the growth-inhibitory effects of adenosine analogues on L1210 and Sarcoma 180 cells in culture," Cancer Res., 36:379-383.	
/L.C./	36	Haimovitz-Friedman, A., Kan, C.C., Ehleiter, D., Persaud, R.S., McLoughlin, M., Fuks, Z. and Kolesnick, R.N., 1994, "Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis," J. Exp. Med., 180:525-535.	
/L.C./	37	Herceg, Z. and Wang, Z.Q., 1999, "Failure of poly (ADP/ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis," Mol. Cell Biol., 19:5124-5133.	
/L.C./	38	Herken, H., Lange, K. and Kolbe, H., 1969, "Brain disorder induced by pharmacological blockade of the pentose phosphate pathway," Biochem. Biophys. Res. Commun., 36:93-100.	
/L.C./	39	Herter, F., Weissman, S.G., Thompson, H.G. et al., 1961, "Clinical experience with 6-aminonicotinamide," Cancer Res. 21:31-37.	
/L.C./	40	Hickman, J.A., 1992, "Apoptosis induced by anticancer drugs," Cancer Metast. Rev., 11:121-139.	
/L.C./	41	Hunting, D., Gowans, B., and Henderson, J.F., 1985, "Effect of 6-AN on cell growth, poly (ADP-ribose) synthesis and nucleotide metabolism," Biochem. Pharmacol., 34:3999-4003.	
/L.C./	42	Janicke, R.V., Sprengart, M.L., Wati, M.R. and Porter, A.G., 1998, "Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis," J. Biol. Chem., 273:9357-9360.	

Examiner Signature	/Lawrence Crane (03/31/2005)
	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 12

Application Number 10/518,003
Filing Date March 14, 2005
First Named Inventor Daniel S. MARTIN
Art Unit 1623
Examiner Name Lawrence E. Crane
Attorney Docket Number 636-C-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	43	Janicke, R.U., Ng, P., Sprengart, M.L., and Porter, A.G., 1998, "Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis," J. Biol. Chem., 273:15540-5.	
/L.C./	44	Jones, M., 1980, "Pyrimidine nucleotide biosynthesis in animals: Genes, enzymes and regulation of UMP synthesis," Ann. Rev. Biochem., 49:253-279.	
/L.C./	45	Kamatani, N., Nelson, Rees, W.A. and Carson, D.A., 1981, "Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme," Proc. Natl. Acad. Sci. USA, 78:1219-1223.	
/L.C./	46	Kass, G.E., Eriksson, J.E., Weis, M., Orrenius, S., and Chow, S.C., 1996, "Chromatin condensation during apoptosis requires ATP," Biochem. J., 318:749-52.	
/L.C./	47	Kerr, J.F.R., Wyllie, A.H., and Currie, A.R., 1972, "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics," Brit. J. Cancer, 26:239-257.	
/L.C./	48	King, M.P., and Attardi, G., 1989, "Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation," Science, 246:500-503.	
/L.C./	49	King, K.L. and Cidlowski, J.A., 1995, "Cell cycle and apoptosis: Common pathways to life and death," J. Cell Biochem., 58:175-180.	
/L.C./	50	Ko et al., 2004, "Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP," Biochemical and Biophysical Research Communications, 269:275.	
/L.C./	51	Kroemer, G., 1997, "Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution," Cell Death Differ., 4:443-456.	
/L.C./	52	Kroemer, G., Zamzami, N., and Susin, S.A., 1997, "Mitochondrial control of apoptosis," Immunol. Today, 18:44-51.	

Examiner
Signature

/Lawrence Crane (date 3/17/2008)
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/518,003
Filing Date	March 14, 2005
First Named Inventor	Daniel S. MARTIN
Art Unit	1623
Examiner Name	Lawrence E. Crane
Attorney Docket Number	636-C-PCT-US

Sheet 7 of 12

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	53	Krug, L.M., Ng, K.K., Kris, M.G., Miller, V.A., Tong, W., Heelan, R.J., Leon, L., Leung, D., Kelly, J., Grant, S.C. and Sirotak, F.M., 2000, "Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin a new antifolate," Clin. Cancer Res., 3493-3498.	
/L.C./	54	Kuida, K., Hayder, T.F., Kuan, C.Y., Gu, Y., Taya, C., Karasuyama, H., Su, M.S.S., Radic, P. and Flavell, R.A., 1998, "Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase activation in mice lacking caspase 9," Cell, 94:325-337.	
/L.C./	55	Lemasters, J.J., 1999, "Necroptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis," Am. J. Physiol., 276:G1-6.	
/L.C./	56	Li, H., Zhu, H., Xu, C.J., 1998, "Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis," Cell, 94:491-501.	
/L.C./	57	Li, W.W., Cole, P., Martin, D., Banerjee, D. and Bertino, J.R., 2000, "Methylthioadenosine phosphorylase (MTAP) status determines sensitivity to L-alanine in human soft tissue sarcoma cell lines and is enhanced by 6-methylmercaptopurine riboside (MMPR)," Proc. Am. Assoc. Cancer Res., 41:240.	
/L.C./	58	Liu, X., Kim, C.N., Yang, J., Jemerson, R. and Wang, X., 1996, "Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C," Cell, 86:147-157.	
/L.C./	59	Lowe, S.W., 1995, "Cancer therapy and p53," Curr. Opin. Oncol., 7:547-553.	
/L.C./	60	Marks, D.I., and Fox, R.M., 1991, "DNA damage, poly(ADP-ribose)lactation and apoptotic cell death as a potential common pathway of cytotoxic drug action," Biochem. Pharmacol. 42:1859-1867.	
/L.C./	61	Martin, D.S., Fugman, R.A., Stolli, R.L. and Hayworth, E., 1975, "Solid tumor animal model therapeutically predictive for human breast cancer," Cancer Chemother. Rep. Part 2, 5:89. 155, #1, December, 1975.	
/L.C./	62	Martin, D.S., Stolli, R.L., and Colofiore, J.R., 1997, "Perspective: The chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically-induced apoptosis," Cancer Invest., 15:372-381.	

Examiner
Signature

/Lawrence Crane (03/31/2006)
Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituta for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
Sheet	8	of	12
		Attorney Docket Number	636-C-PT-US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/L.C./	63	Martin, D., Matei, C., and Koutcher, J., 2000, "Marked enhancement of radiotherapy-induced tumor regression by an NAD antagonist, 6-aminonicotinamide (6-AN)," <i>Proc. Am. Assoc. Cancer Res.</i> , 41:283 (Abstract 1800).		
/L.C./	64	Modica Napolitano, J.S. and Aprille, J.R., 2001, "Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells," <i>Adv. Drug Deliv. Rev.</i> , 49:63-701.		
/L.C./	65	National Institute of Health Consensus Development Conference Statement, 2001, "Adjuvant Therapy for Breast Cancer, November 1-3, 2000," <i>J. Natl. Cancer Inst.</i> , 93:979-989.		
/L.C./	66	Nguyen, B.T., El Sayed, Y.M., and Sadee, W., 1984, "Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells," <i>Cancer Res.</i> , 44:2272-2277.		
/L.C./	67	Nicotera, P. and Leist, M., 1997, "Mitochondrial signals and energy requirement in cell death," <i>Cell Death Differ.</i> , 4:516.		
/L.C./	68	Nobori, T., Karras, J.G., Della Ragione, F., Waltz, T.Z., Chen P.P. and Carson, D.A., 1991, "Absence of methylthioadenosine phosphorylase in human gliomas," <i>Cancer Res.</i> , 51:3193-3197.		
/L.C./	69	Nobori, T., Szinal, I., Amox, D., Parker, B., Olopade, O.I., Buchhagen, D.L. and Carson, D.A., 1993, "Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers," <i>Cancer Res.</i> , 53:1098-1101.		
/L.C./	70	Presta, M., Rusnati, M., Belleri, M., Morbedelli, L., Ziche, M. and Ribatti, D., 1999, "Purine analogue 6-methylmercaptapurine riboside inhibits early and late phases of the angiogenesis process," <i>Cancer Res.</i> , 59:2417-2424.		
/L.C./	71	Raffray, M. and Cohen, G.M., 1997, "Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death?" <i>Pharmacol. Ther.</i> , 75:153-177.		
/L.C./	72	Reed, J.C., 1995, "Regulation of apoptosis by bcl-2 family proteins and its role in cancer and drug resistance," <i>Curr. Opin. Oncol.</i> , 7:541-546.		

Examiner Signature	/Lawrence Crane (10/23/2008)
	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
Sheet 9	of 12	Attorney Docket Number	636-C-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	73	Roy, N., Dveraux, Q.L., Takahashi, R., Salvesen, G.S. and Reed, J.C., 1997, "The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases," EMBO J., 16:6914-6925.	
/L.C./	74	Sausville, E.A. and Feigal, E., 1999, "Evolving approaches to cancer drug discovery and development at the National Cancer Institute," USA Ann. Oncol., 10:1287-1291.	
/L.C./	75	Schmitt, C.A. and Lowe, S.W., 2002, "A senescence program controlled by p53 and p16 Ink4a contributed to the outcome of cancer therapy," Cell, 109:335-346.	
/L.C./	76	Schmitt, C.A. and Lowe, S.W., 2002, "Apoptosis and chemoresistance in transgenic cancer models," J. Mol. Med., 80:137-146.	
/L.C./	77	Schraufstatter, I.U., Hinshaw, D.B., Hyslop, P.S., Spragg, R.H., and Cochrane, C.G., 1986, "Oxidant injury of cells DNA strand-breaks activate polyadenosine diphosphate polymerase and lead to depletion of nicotinamide adenine dinucleotide," J. Clin. Invest., 77:1312-1320.	
/L.C./	78	Scudiero, D.A., Monks, A., and Sausville, E.A., 1998, "Cell line designation change: Multidrug-resistant cell line in the NCI anticancer screen," J. Natl. Cancer Inst., 90:862.	
/L.C./	79	Serafino, A., Sinibaldi-Vallebono, P., Lazzarino, G., Tavazzi, B., DiPiero, D., Rosi, G. and Ravagnan, G., 2000, "Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis," Anticancer Res., 20:3383-3394.	
/L.C./	80	Shantz, G.D., Smith, C.M., Fontanella, L.J., Lau, H.K.F., and Henderson, J.F., 1973, "Inhibition of purine nucleotide metabolism by 8-methylmercaptapurine ribonucleoside and structurally related compounds," Cancer Res., 33:2867-2871.	
/L.C./	81	Shimizu, S., Equichi, Y., Kamike, W., Itoh, Y., Hasegawa, J., Yamabe, K., Otsuid, Y., Matsuda, H. and Tsujimoto, Y., 1996, "Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by bcl-2 and bcl-x," Cancer Res., 56:2161-2166.	
/L.C./	82	Sirotnak, F.M., De Graw, J.I., Colwell, W.T. and Piper, J.R., 1998, "A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice," Cancer Chemother. Pharmacol., 42:313-318.	

Examiner Signature	/Lawrence Crane/ Date 3/17/2008	Considered
---------------------------	---------------------------------	-------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
Sheet	10	of	12
		Attorney Docket Number	636-C-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	83	Staunton, M.J. and Gaffney, E.F., 1998, "Apoptosis: basic concepts and potential significance in human cancer," Arch. Pathol. Lab. Med., 122:310-319.	
/L.C./	84	Stolfi, R.L., Martin, D.S. and Fugman, R.A., 1971, "Spontaneous murine mammary adenocarcinoma: Model system for the evaluation of combined methods of therapy," Cancer Chemother. Rep. Part 1, 55:239.	
/L.C./	85	Stolfi, R.L., Stolfi, L.M., Sawyer, R.C., and Martin, D.S., 1988, "Chemotherapeutic evaluation using clinical criteria in spontaneous, autochthonous murine breast tumors," J. Nat. Cancer Inst., 80:52-5.	
/L.C./	86	Street, J.C., Mahmoud, V., Ballon, D., Alfieri, A.A., and Koutcher, J.A., 1996, "13C and 31p NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro," J. Biol. Chem., 271:4113-4119.	
/L.C./	87	Street, J.C., Alfieri, A.A., and Koutcher, J.A., 1997, "Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro," Cancer Res., 57:3956-3962.	
/L.C./	88	Susin, S.A., Zamzami, N., Castedo, M., Hirsch, T., Marchetti, P., Macho, A., Dauges, E., Gauskens, M. and Kroemer, G., 1996, "Bcl-2 inhibits the mitochondrial release of an apoptogenic protease," J. Exp. Med., 184:1331-1342.	
/L.C./	89	Tanizawa, A., Kubota, M., Hashimoto, H., Shimizu, T., Takimoto, T., Kitoh, T., Akiyama, Y., and Mikawa, H., 1989, "VP-16-induced nucleotide pool changes and poly (ADP-ribose) synthesis: The role of VP-16 in interphase death," Exp. Cell Res., 185:237-246.	
/L.C./	90	Tian, W-N., Braunstein, L.D., Apse, K., Pang, J., Rose, M., Tian, X., and Stanton, R.C., 1998, "Importance of Glucose-6-phosphate dehydrogenase activity for cell growth," J. Biol. Chem., 273:10609-10617.	
/L.C./	91	Tian, W-N., Braunstein, L.D., Apse, K., Pang, J., Rose, M., Tian, X., and Stanton, R.C., 1999, "Importance of glucose-6-phosphate dehydrogenase activity in cell death," Am. J. Physiol., 276 (Cell Physiol. 45):C1121-C1131.	
/L.C./	92	Tyagi, A.K. and Cooney, D.A., 1984, "Biomedical pharmacology, metabolism and mechanism of action of L-alanosine, a novel, natural antitumor agent," Adv. Pharmacol. Chemother. 20:69-121.	

Examiner Signature	/Lawrence E. Crane (03/31/2008)
	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 12

Application Number	10/518,003
Filing Date	March 14, 2005
First Named Inventor	Daniel S. MARTIN
Art Unit	1623
Examiner Name	Lawrence E. Crane
Attorney Docket Number	636-C-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	93	Warnick, C.T., and Patterson, A.R.P., 1973, "Effect of methylthioinosine on nucleoside concentration in L5158 cells," Cancer Res., 33:1711-1715.	
/L.C./	94	Wielinga, P.R., Reid, G., Chella, E.E., van der Heijden, L., van Deemter, L., De Haas, M., Mol, C., Kull, A.J., Groeneweld, E., Schuetz, J.D., Brouwer, C., De Abreu, R.A., Wijnholds, J., Beijnen, J.H. and Borst, P., 2002, Thiopurine metabolism and identification of the Thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells," Mol. Pharm., 62:1321-1331.	
/L.C./	95	Williams-Ashman, H.G., Seidenfeld, J. and Galletti, P., 1982, "Trends in the biochemical pharmacology of 5'-deoxy-5'-methylthioadenosine," Biochem. Pharmacol., 31:277-288.	
/L.C./	96	Woods, R.A., Henderson, R.M., and Henderson, J.F., 1978, "Consequences of inhibition of purine biosynthesis de novo by 6-methylmercaptopurine ribonucleoside in cultured lymphoma L5178 cells," Euro. J. Cancer, 14:765-70.	
/L.C./	97	Wyllie, A.H., 1993, "Apoptosis [The 1992 Frank Rose Memorial Lecture]," Br. J. Cancer., 67:205-208.	
/L.C./	98	Xiang, J., Chao, T. and Korsmyer, S.J., 1996, "Bax-induced cell death may not require interleukin 1-converting enzyme-like proteases," Proc. Natl. Acad. Sci. USA, 93:14359-14563.	
/L.C./	99	Yoshida, H., Kong, Y.Y., Yoshida, R., Elia, A.J., Hakem, R., Penninger, J.M. and Mak, T.W., 1998, "Apaf-1 is required for mitochondrial pathways of apoptosis and brain development," Cell, 94:739-750.	
/L.C./	100	Young, I., Young, G.L., Wiley, J.S. and van der Weyden, M.B., 1985, "Nucleoside transport and cytosine arabinoside (ara C) metabolism in human T lymphoblasts resistant to ara C, thymidine and 6-methylmercaptopurine riboside," Eur. J. Cancer Clin. Oncol., 21(9):1077-1082.	
/L.C./	101	Zamzami, N., Susin, S.A., Marchetti, P., Hirsch, T., Gomez-Monterrey, I., Castedo, M., and Kroemer, G., 1996, "Mitochondrial control of nuclear apoptosis (see co-ents)," J. Exp. Med., 183:1533-44.	
/L.C./	102	Zou, H., Li, Y., Liu, X., and Wang, X., 1999, "An apaf-1-cytochrome c multimeric complex is a functional aptosome that activates procaspase-9," J. Biol. Chem., 274:11549-11556.	

Examiner Signature

/Lawrence Crane (103/31/2005)

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,003
		Filing Date	March 14, 2005
		First Named Inventor	Daniel S. MARTIN
		Art Unit	1623
		Examiner Name	Lawrence E. Crane
Sheet 12	of 12	Attorney Docket Number	636-C-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/L.C./	103	European Communication for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, European Application No. 01986104.6 (Atty. Dkt. #636-A-PCT-EPO), Filed July 2, 2003, Dated September 6, 2007.	
/L.C./	104	U.S. Office Action for MARTIN et al., U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B), Filed June 13, 2002, Dated November 19, 2003.	
/L.C./	105	U.S. Office Action for MARTIN et al., U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B), Filed June 13, 2002, Dated June 15, 2005.	
/L.C./	106	U.S. Office Action for MARTIN et al., U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B), Filed June 13, 2002, Dated June 15, 2006.	
/L.C./	107	Notice of Allowance and Fee(s) Due and Notice of Allowability, for MARTIN et al., U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B), Filed June 13, 2002, Dated August 20, 2007.	
/L.C./	108	NIH R01 Grant Information for 1R01CA098505—1A3, PI Jason Koutcher, Project Title "Cytocidal Therapy In Vivo for Drug-Resistant Tumors," previously submitted for U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B).	
/L.C./	109	National Cancer Institute RAID Grant Information, PI Maiyer Rizvi, previously submitted for U.S. Serial No. 10/172,346 (Atty. Dkt. #636-B).	

Examiner Signature	/Lawrence Crane	Date 03/31/2008	Considered
---------------------------	-----------------	------------------------	-------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.